FHA
ORMP icon

Flagship Harbor Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

Flagship Harbor Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-700
Closed -$2K – 1919
2018
Q4 		$2K Buy
+700
New +$2.9K ﹤0.01% 1658

Other funds holding ORMP

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
RPC
Rossmore Private Capital Glastonbury, Connecticut $1.14B AUM 23.53% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Flagship Harbor Advisors's ORMP Position: Q1 2019 in Review

Flagship Harbor Advisors sold out of Oramed Pharmaceuticals (ORMP) in Q1 2019, closing a stake of 700 shares — an estimated $2K sold.

Flagship Harbor Advisors first reported a position in ORMP in Q4 2018 and held it in 1 quarter. The position peaked at $2K in Q4 2018. 25 funds tracked by Wall St. Rank hold ORMP as of Q1 2019.

  • Flagship Harbor Advisors reported no remaining Oramed Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Flagship Harbor Advisors sold 700 Oramed Pharmaceuticals shares in Q1 2019, an estimated $2K.
  • Flagship Harbor Advisors first reported a position in Oramed Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Flagship Harbor Advisors's Oramed Pharmaceuticals position peaked at $2K in Q4 2018.
  • 25 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2019.

Based on Flagship Harbor Advisors's 13F filing for Q1 2019, filed 15 Apr 2019.